Paige, a global leader in AI-based diagnostic software in pathology, today announced that it has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most promising private companies in the industry.

“We are honored to be named as one of the Fierce 15 companies of 2020, which is a testament to our team’s innovation, creativity and perseverance even in the face of intense competition and a global pandemic,” said Leo Grady, Ph.D., Chief Executive Officer, Paige. “Paige sits among the most innovative medical technology companies at a time of rapid innovation in the broader healthcare space. We are excited to grow and expand our team this year as we build a transformational portfolio of computational pathology products to serve clinical needs and drive precision medicine.”

In the past year, Paige raised more than $100 million to transform and grow the Company’s portfolio of digital and computational pathology products for cancer while securing FDA clearance for its FullFocus™ digital pathology image viewer in the U.S. and achieving CE marks for its Paige Prostate and Paige Breast diagnostic software.

“Each member of this year’s class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant — and all have the potential to deliver changes in healthcare that promise to outlast this pandemic,” said Conor Hale, associate editor of Fierce Medtech.

An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

The full list of winners can be viewed online here.

About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

For additional information, please visit:,, Twitter and LinkedIn.

About Fierce Medtech
Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories.